Mass Spectrometry Metabolomics Based Biomarkers for Detection of Autism Spectrum Disorder from Patient Blood Samples – IMFAR 2014 [PDF]
 /  Posters / Posters & Publications / Mass Spectrometry Metabolomics Based Biomarkers for Detection of Autism Spectrum Disorder from Patient Blood Samples – IMFAR 2014 [PDF]

Mass Spectrometry Metabolomics Based Biomarkers for Detection of Autism Spectrum Disorder from Patient Blood Samples – IMFAR 2014 [PDF]

Presented at the 2014 International Meeting for Autism Research in Atlanta, Georgia in May 2014.

The diagnosis of autism spectrum disorder (ASD) at the earliest age possible is important for initiating optimally effective intervention. Patients can be reliably diagnosed through behavioral testing at about 2 years of age. However, in the United States, the average age of diagnosis is around 4 years. Using a non-targeted mass spectrometry-based metabolomic analysis of blood plasma, we demonstrated that some features with differential abundance in ASD vs. TD patients (4-6 years old) can be used to derive classification models with 81% accuracy.

Related Posts

(608) 441-8187

504 S. Rosa Rd. Suite 150
Madison, WI 53719

contact@NeuroPointDx.com

FOLLOW US